Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
Laurie HerviouSara OvejeroFanny IzardOuissem Karmous-GadachaClaire GourzonesCeline BellangerEva De SmedtAnqi MaLaure VincentGuillaume CartronJian JinElke De BruyneCharlotte GrimaudEric JulienJérôme MoreauxPublished in: Clinical epigenetics (2021)
Altogether, our data indicate that the up-regulation of the epigenetic enzyme SETD8 is associated with a poor outcome and the deregulation of major signaling pathways in MM. Moreover, we provide evidences that myeloma cells are dependent on SETD8 activity and its pharmacological inhibition synergizes with melphalan, which could be beneficial to improve MM treatment in high-risk patients whatever their status for p53.
Keyphrases
- multiple myeloma
- newly diagnosed
- end stage renal disease
- induced apoptosis
- signaling pathway
- ejection fraction
- chronic kidney disease
- dna methylation
- gene expression
- prognostic factors
- peritoneal dialysis
- cancer therapy
- big data
- endoplasmic reticulum stress
- cell proliferation
- oxidative stress
- patient reported
- replacement therapy